1. Home
  2. REGN vs CMI Comparison

REGN vs CMI Comparison

Compare REGN & CMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • CMI
  • Stock Information
  • Founded
  • REGN 1988
  • CMI 1919
  • Country
  • REGN United States
  • CMI United States
  • Employees
  • REGN N/A
  • CMI N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • CMI Industrial Machinery/Components
  • Sector
  • REGN Health Care
  • CMI Industrials
  • Exchange
  • REGN Nasdaq
  • CMI Nasdaq
  • Market Cap
  • REGN 59.5B
  • CMI 54.9B
  • IPO Year
  • REGN 1991
  • CMI N/A
  • Fundamental
  • Price
  • REGN $576.66
  • CMI $423.12
  • Analyst Decision
  • REGN Buy
  • CMI Buy
  • Analyst Count
  • REGN 23
  • CMI 13
  • Target Price
  • REGN $795.04
  • CMI $404.50
  • AVG Volume (30 Days)
  • REGN 1.2M
  • CMI 878.4K
  • Earning Date
  • REGN 10-28-2025
  • CMI 11-04-2025
  • Dividend Yield
  • REGN 0.61%
  • CMI 1.89%
  • EPS Growth
  • REGN 5.03
  • CMI 54.79
  • EPS
  • REGN 39.67
  • CMI 21.26
  • Revenue
  • REGN $14,214,200,000.00
  • CMI $33,720,000,000.00
  • Revenue This Year
  • REGN N/A
  • CMI N/A
  • Revenue Next Year
  • REGN $4.74
  • CMI $5.99
  • P/E Ratio
  • REGN $14.53
  • CMI $19.91
  • Revenue Growth
  • REGN 5.38
  • CMI N/A
  • 52 Week Low
  • REGN $476.49
  • CMI $260.02
  • 52 Week High
  • REGN $1,024.36
  • CMI $440.51
  • Technical
  • Relative Strength Index (RSI)
  • REGN 51.13
  • CMI 54.50
  • Support Level
  • REGN $541.00
  • CMI $400.72
  • Resistance Level
  • REGN $577.17
  • CMI $440.51
  • Average True Range (ATR)
  • REGN 19.79
  • CMI 10.09
  • MACD
  • REGN -1.32
  • CMI -2.66
  • Stochastic Oscillator
  • REGN 46.31
  • CMI 56.28

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About CMI Cummins Inc.

Cummins is a leading manufacturer of diesel and other engines used in heavy- and medium-duty commercial trucks, off-highway equipment, and locomotives, in addition to prime power and standby generators. The company also sells powertrain components, which include filtration products, transmissions, turbochargers, aftertreatment systems, and fuel systems. Sales are approximately 60% US and Canada and 40% rest of the world. Much of Cummins' foreign sales (China, India, and so forth) are through joint ventures. The company operates 650 distributors and over 19,000 dealer locations across 190 countries. Cummins' business model is unique as it competes with many of its heavy-duty truck manufacturer customers, which also make their own engines.

Share on Social Networks: